Watch FDMT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
36
FLAG · insiders 26, shorts 45
Insiders, 90 days
−$1.1M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $745.2MP/E —DIV YIELD —FCF YIELD —REV TTM $92M +278712.1%NET INCOME −$179.2MNET CASH $50.8M52W 6.60 – 16.76SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3.8M | +25106.7% | — | −$77M | −$72.9M | — | -1.04 | −$70M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | $3M | +21664.3% | — | −$73.6M | −$68.8M | — | -1.01 | −$68.1M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | $85.1M | +8508900.0% | — | $14.7M | $19.4M | — | 0.43 | $28.6M | −$70K | $28.6M | Mar 18 |
| Q3 2025 · Sep 30 | $90K | +2900.0% | — | −$61.2M | −$56.9M | — | -1.01 | −$46.5M | −$91K | −$46.4M | Nov 10 |
| Q2 2025 · Jun 30 | $15K | +200.0% | — | −$59.5M | −$54.7M | — | -0.98 | −$43.4M | $66K | −$43.4M | Aug 13 |
| Q1 2025 · Mar 31 | $14K | −50.0% | — | −$53.6M | −$48M | — | -0.86 | −$47.8M | $631K | −$48.4M | Aug 13 |
| Q4 2024 · Dec 31derived | $1K | — | — | −$56.1M | −$49.7M | — | -0.90 | −$45.9M | $949K | −$46.8M | Mar 18 |
| Q3 2024 · Sep 30 | $3K | −100.0% | — | −$51.1M | −$43.8M | — | -0.79 | −$29.4M | $1.8M | −$31.2M | Nov 10 |
| Q2 2024 · Jun 30 | $5K | — | — | −$42.5M | −$35M | — | -0.63 | −$30.2M | $349K | −$30.6M | Nov 10 |
| Q1 2024 · Mar 31 | $28K | — | — | −$38.1M | −$32.4M | — | -0.66 | −$29.1M | $710K | −$29.8M | Nov 10 |
| Q4 2023 · Dec 31derived | −$19K | — | — | −$36.7M | −$32.3M | — | -0.77 | −$24.6M | $549K | −$25.2M | Feb 28 |
| Q3 2023 · Sep 30 | $20.2M | — | — | −$14M | −$10.3M | — | -0.24 | −$1.2M | $405K | −$1.6M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $85.2M | — | −$159.5M | −$140.1M | -164.4% | -2.42 | −$109.1M | $536K | −$109.6M | — | — |
| FY2024 · to Dec 31 | $37K | — | −$187.8M | −$160.9M | -434778.4% | -2.98 | −$134.6M | $3.8M | −$138.4M | — | — |
| FY2023 · to Dec 31 | $20.7M | — | −$112.9M | −$100.8M | -486.6% | -2.58 | −$75.8M | $2.8M | −$78.6M | — | — |
| FY2022 · to Dec 31 | $3.1M | — | −$110M | −$107.5M | -3435.4% | -3.32 | −$86.7M | $11.5M | −$98.2M | — | — |
| FY2021 · to Dec 31 | $18M | — | −$71.3M | −$71.3M | -395.4% | -2.57 | −$69.1M | $9.1M | −$78.2M | — | — |
| FY2020 · to Dec 31 | $13.6M | — | −$56.7M | −$56.7M | -416.5% | -8.82 | −$50.9M | $1M | −$51.9M | — | — |
Every number comes from 4D Molecular Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.